Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alan Mark Goldberg

Affiliations

  • Director at Immunogen Inc (IMGN), 2019-07-01
  • Director at Blueprint Medicines Corp (BPMC), 2019-06-20
  • Director at Idera Pharmaceuticals Inc. (IDRA), 2019-06-06
  • Director at Glycomimetics Inc (GLYC), 2019-05-21
  • Director at Audentes Therapeutics Inc. (BOLD), 2019-02-08
  • Director at Atyr Pharma Inc (LIFE), 2017-05-11
  • Evp, Medical & Reg. Strategy at Synageva Biopharma Corp (GEVA), 2014-09-19
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
IDRA $3.19 10,000 Director 10,000 2018-12-19 Filing
IMGN $5.76 30,000 Director 53,800 2018-11-06 Filing
IMGN $1.80 20,000 Director 23,800 2016-12-15 Filing
GLYC $4.77 10,397 Director 11,497 2016-03-04 Filing
IMGN $11.27 3,000 Director 3,800 2012-11-08 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
GEVA $65.24 790 562 2014-09-19 Filing
GEVA $65.06 4,200 562 2014-09-17 Filing
GEVA $65.01 9,379 562 2014-09-16 Filing
GEVA $80.00 21,597 459 2014-06-11 Filing
GEVA $61.02 413 267 2013-12-03 Filing